← All indications
Neuromyelitis Optica
A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.
Drugs by status
Approved for this indication (2)
Phase 4 trials (8)
Phase 3 trials (12)
Phase 2 trials (22)
Phase 1 trials (19)
- abx-1431
- C1 Esterase Inhibitor (Human)
- alpha-1 antitrypsin
- bevacizumab
- ublituximab
- anti-cd19/20-car vector-transduced t cells
- cd19 car-t cells
- tolerogenic dendritic cells loaded with myelin peptides
- fludarabine
- hbm9161
- ct-rd06
- equecabtagene autoleucel
- lp-168
- lcar-aio cells
- ucar-t cells
- cd20/bcma-directed car-t cells
- extracellular vesicles derived from human induced neural stem cell
- universal bcma car-t
- rd06-05
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (21)
- Roche
- MedImmune
- Alexion
- Chugai
- RemeGen
- University of London
- Newcastle University
- NHS Lothian
- Northwestern University
- University of Liverpool
- University of Manchester
- University of Nottingham
- University of Birmingham
- University of Bristol
- Cardiff University
- Peking University
- Salford Royal Foundation NHS Trust
- Tianjin Medical University
- Isfahan University
- University of Oxford
- Moorgreen Hospital, Southampton
Organization Involved with Phase 2 Indications (13)
- Acorda Therapeutics
- Nihon Pharmaceutical Co., Ltd
- National Cancer Institute (NCI)
- University of Washington
- Johns Hopkins University
- Nanjing Medical University
- Nanjing University
- Xuzhou Medical University
- Mayo Clinic
- Icahn School of Medicine at Mount Sinai
- Beike Biotech
- Guthy Jackson Charitable Foundation
- Reistone Biopharma Company Limited